Veradermics director trust buys 294,117 shares

Veradermics, Inc director John W. Childs, through the John W. Childs 2013 Revocable Trust, indirectly bought 294,117 shares of Common Stock at $17.00 per share in an open‑market purchase.

Rhea-AI Filing Summary

Veradermics, Inc director John W. Childs, through the John W. Childs 2013 Revocable Trust, indirectly bought 294,117 shares of Common Stock at $17.00 per share in an open‑market purchase. This amended Form 4 corrects the earlier report by clarifying that the shares are held via the revocable trust rather than J.W. Childs Associates (FL), L.P.

Insider Trade Summary

Net Buyer: 294,117 shares

Net Buy 1 txn

Insider CHILDS JOHN W

Role Director

Bought 294,117 shs ($5.00M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	294,117	$17.00	$5.00M

Holdings After Transaction: Common Stock — 294,117 shares (Indirect, See Footnote)

Footnotes (2)

1. F1. This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on February 5, 2026 (Original Form 4). The Original Form 4 inadvertently misstated that 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. However, as reflected in this amendment, 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through the John W. Childs 2013 Revocable Trust, and no shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P.
2. F2. Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veradermics (MANE) report in this Form 4/A?

Veradermics reported an amended Form 4 showing an indirect open-market purchase of 294,117 shares of Common Stock at $17.00 per share. The shares are attributed to a revocable trust associated with director John W. Childs.

Who is involved in the Veradermics (MANE) Form 4/A transaction?

The filing involves director John W. Childs. The 294,117 Veradermics Common Stock shares are held by the John W. Childs 2013 Revocable Trust, where he is trustee and may be deemed to hold voting and dispositive power.

How many Veradermics (MANE) shares were acquired and at what price?

The amended Form 4 reports that 294,117 shares of Veradermics Common Stock were indirectly acquired in an open-market purchase at a price of $17.00 per share, all held through the John W. Childs 2013 Revocable Trust.

What does this Veradermics (MANE) Form 4/A amendment correct?

The amendment corrects the previously reported nature of indirect ownership. It clarifies that the 294,117 shares were acquired through the John W. Childs 2013 Revocable Trust, not through J.W. Childs Associates (FL), L.P., as initially stated.

Does the Veradermics (MANE) Form 4/A change the number of shares owned?

The amendment keeps the reported 294,117 Veradermics Common Stock shares the same but updates who holds them indirectly. It specifies that these shares are held by the John W. Childs 2013 Revocable Trust with Childs as trustee.

Is the Veradermics (MANE) insider ownership in this filing direct or indirect?

The ownership reported in this Form 4/A is indirect. The 294,117 Veradermics Common Stock shares are held by the John W. Childs 2013 Revocable Trust, where John W. Childs serves as trustee with potential voting and dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHILDS JOHN W

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		P		294,117(1)	A	$17	294,117(1)	I	See Footnote(1)(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on February 5, 2026 (Original Form 4). The Original Form 4 inadvertently misstated that 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. However, as reflected in this amendment, 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through the John W. Childs 2013 Revocable Trust, and no shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P.

2. Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.